Who We Are
Cogent Biosciences is a publicly traded biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis (SM), which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling. We are currently enrolling two Phase 2 clinical trials for patients with SM and a global Phase 3 trial for GIST patients.
Our Team
https://cogent.culturehq.com
We are looking for a staff accountant to join our growing finance team located in Waltham, Massachusetts. This role reports directly to the Senior Manager, Accounting and will contribute to critical operational and accounting functions, including month-end close activities and accounts payable. This role requires a solid accounting background combined with strong analytical skills.
Responsibilities
- Assist in the month-end financial close process, including preparing journal entries, analyses, account reconciliations covering areas such as cash, prepaid expenses and accrued expenses.
- Assist with invoice data entry and vendor management in ERP and purchasing system.
- Assist with VAT and other tax reporting and compliance requirements.
- Assist with monthly credit card reconciliation.
- Assisting with the preparation of SEC reporting documents (i.e. 10-K, 10-Q).
- Support and adhere to strong internal control policies and procedures and identify and implement process improvements to enhance efficiency and accuracy in financial reporting.
- Assist with quarterly reviews and annual audits by providing necessary documentation and responding to auditor inquiries.
- Assist with ad-hoc accounting projects.
Qualifications
- Bachelor’s degree in Accounting.
- Strong understanding of U.S. GAAP.
- Microsoft office skills required, including Excel.
- CPA license preferred, but not required.
- Experience in the Biotech industry preferred, but not required.
- Big 4 public accounting experience preferred, but not required.
Our Locations
Waltham, MA: Our Boston office includes an open office layout that has recently undergone a makeover designed for collaboration and giving our employees the best work place possible. Free access is provided for both on-site parking and gym facilities in the building.
Boulder, CO: We have just moved into our new state-of-the art Research Facility in the fast-growing biopharmaceutical hub in the greater Denver/Boulder corridor. Our CEO is based full-time in this location and we are proud to call this the home of Cogent’s discovery research organization.
Our Offer To You
To attract the very best talent, we offer a generous benefits package that includes competitive pay, performance-based bonus, stock options, insurance coverage (health, dental, life, and disability), competitive time-off, a 401(k) plan, and commuter/parking benefits.
We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need.
What We Do
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.